Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

My connections

Alison Banham

BA, MA, DPhil (Oxon), FRCPath


Professor of Haemato-oncology

  • Head of NDCLS

The study of transcriptional de-regulation in B-cell malignancies and the development of novel antibodies for cancer therapy.

Alison Banham is currently Professor of Haemato-oncology and Head of the Nuffield Division of Clinical Laboratory Sciences, within the Radcliffe Department of Medicine at the University of Oxford. Her academic qualifications include BA, MA and D.Phil. (PhD) degrees from the University of Oxford and Fellowship of the Royal College of Pathologists.  

Professor Banham is a founder member and Vice President of the European Network of Monoclonal Antibody Producing Laboratories. She is internationally recognised for her expertise in the production and characterisation of monoclonal antibodies and has written guidelines to promote effective antibody validation. She has also made key contributions to the design and delivery of EuroMabNet workshops that teach young scientists how to validate antibodies.  

Since 1995 Professor Banham's main research focus has been within the field of cancer, particularly aggressive B-cell malignancies, focussing initially on the identification and characterisation of novel diagnostic and prognostic biomarkers. These have included the FOXP family of forkhead transcription factors (FOXP1-4) and the cancer testis antigen PASD1. These de-regulated transcription factors have functional roles in tumour biology and strategies are being investigated to enable their future therapeutic targeting in diffuse large B-cell lymphoma and multiple myeloma.  

Professor Banham's team are also generating novel therapeutic antibodies. These include antibodies targeting the tumour vasculature, in particular the Notch ligand Jagged-1 and the adhesion G-protein coupled receptor ELTD1. She is also pursuing the development of TCR mimic antibodies which recognise peptides from intracellular tumour proteins that are presented on the cell surface by MHC class I molecules. This enables targeting of the intracellular proteome and antibodies to the p53 oncosuppressor are being further characterised.

False False

5

Recent Publications

5 View 155 more »

ORCID

0000-0002-3197-273X